11 May 2021
Oxford Immunotec’s T-SPOT.COVID Test is Used in the COV-AD Clinical Study to Investigate the Immunological Response to SARS-CoV-2 Infection in Patients with Primary and Secondary Antibody Deficiency
27 Apr 2021
Oxford Immunotec’s T-SPOT®Discovery SARS-CoV-2 Test is Used in UK Com-COV Clinical Trial to Investigate the T Cell Response in Different Combinations of Approved COVID-19 Vaccines for the First and Second Doses
04 Mar 2021
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID , a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection
Dr. Juzar Ali discusses the T-SPOT®.TB test’s Borderline result category and its clinical utility in helping to reduce the risk of misclassifying patients whose results are around the test’s established cut-offs for Positive or Negative. This video discusses the utility and significance of the T-SPOT.TB test’s Borderline result category.
Diagnosing TB in the Immunocompromised: What’s New?
The risk of progression from Latent TB infection (LTBI) to active TB is higher amongst immunocompromised patients — who are they? Webinar covers an update on TB testing methods amongst immunocompromised patients and the clinical utility of IGRAs in this patient population group.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.